Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy.
The house dust mite is a major cause of respiratory allergy worldwide. The management of mite allergy is based on avoidance measures, drug treatment, and allergen immunotherapy, but only allergen immunotherapy is able to modify the natural history of the disease. Injectable subcutaneous immunotherapy was introduced a century ago, while sublingual immunotherapy was proposed in the 1980s and emerged in the ensuing years as an effective and safe option to subcutaneous immunotherapy. However, the quality of the extracts to be used in allergen immunotherapy is crucial for the success of treatment. The mite extract for sublingual immunotherapy known as Staloral 300 was developed to offer optimal characteristics concerning the mite culture medium, standardization, and allergen dose. Double-blind, placebo-controlled trials with Staloral 300 have provided a substantial part of the clinical evidence analyzed in a meta-analysis of the efficacy of allergen immunotherapy in mite-induced rhinitis and asthma. Safety and tolerability are very good, mild local reactions in the mouth being the most common side effect. This makes it feasible to carry out sublingual immunotherapy for the 3-5-year duration needed to achieve long-lasting tolerance to the specific allergen. The performance of Staloral 300 may provide optimal conditions for an effective and safe sublingual immunotherapy in patients with mite-induced respiratory allergy.
Medical and Scientific and Regulatory Department, Stallergenes, Milan, Italy.
Franco
F
Frati
Cristoforo
C
Incorvaia
Marie
M
David
Silvia
S
Scurati
Simona
S
Seta
Guglielmo
G
Padua
Eleonora
E
Cattaneo
Carlo
C
Cavaliere
Alessia
A
Di Rienzo
Ilaria
I
Dell'Albani
Paola
P
Puccinelli
D000818:Animals; D001249:Asthma / Q000628:therapy; D003362:Cost-Benefit Analysis; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000191:economics / Q000592:standards*; D006801:Humans; D039981:Pyroglyphidae / Q000276:immunology*; D012221:Rhinitis, Allergic, Perennial / Q000628:therapy; D006255:Rhinitis, Allergic, Seasonal / Q000628:therapy